IDH2 and acute myeloid leukemia: In patients with AML who are treated with combinations based on venetoclax (a BCL-2 inhibitor), NPM1 and IDH2 mutations are associated with high response rates and durable remissions, while the activation of the FLT3, RAS, and TP53 signaling pathways seems to be linked to resistance development [45].